Pearson, Ackman appeal to shareholders after Allergan rejects Valeant's $47B offer | PharmaBoardroom
written on 14.05.2014
Tags:
,

Pearson, Ackman appeal to shareholders after Allergan rejects Valeant's $47B offer

TAGS: ,

Valeant CEO J. Michael Pearson, a serial acquirer, knows how to play the M&A game. After Allergan earlier this week officially spurned his company's $47 billion offer, he and partner Bill Ackman were ready with their next moves.

Latest Report